

Neutropenia During Tocilizumab Treatment Is Not Associated With Infection Risk in Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis

Manuela Pardeo, MD,^{1*} Jianmei Wang, PhD,^{2*} Nicolino Ruperto, MD, MPH,³ Prof. Ekaterina Alexeeva, MD, PhD,⁴ Prof. Vyacheslav Chasnyk, MD,⁵ Prof. Rayfel Schneider, MBBCh,⁶ Prof. Gerd Horneff, MD,⁷ Prof. Hans-Iko Huppertz, MD,⁸ Kirsten Minden, MD,⁹ Prof. Karen Onel, MD,¹⁰ Lawrence Zemel, MD,¹¹ Alan Martin, MD,¹² Isabelle Koné-Paut, MD,¹³ Prof. Antigoni Siamopoulou-Mavridou, MD,¹⁴ Assoc. Prof. Clovis A. Silva, MD, PhD,¹⁵ Benjamin Porter-Brown, MBBS, DPM, MFPM,² Kamal N. Bharucha, PhD, MD,^{16¶} Hermine I. Brunner, MD, MSc,¹⁷ and Fabrizio De Benedetti, MD, PhD, Head¹ for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

¹IRCCS Ospedale Pediatrico Bambino Gesù, Division of Rheumatology, Rome, Italy; ²Roche Products Ltd., Welwyn Garden City, United Kingdom; ³IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Genoa, Italy; ⁴Federal State Autonomous Institution “National Medical Research Center of Children's Health” of the Ministry of Health of the Russian Federation, Department of Rheumatology, and Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov, First Moscow State Medical University of the Ministry of Health of the Russian Federation, Department of Pediatrics and Pediatric Rheumatology, Moscow, Russian Federation; ⁵Saint-Petersburg State Pediatric Medical University, Department of Hospital Pediatrics, Saint-Petersburg, Russian Federation; ⁶Hospital for Sick Children, University of Toronto, Department of Pediatrics, Division of Rheumatology, Toronto, ON, Canada; ⁷Asklepios Klinik Sankt Augustin, Centre for General Pediatrics and Neonatology, Sankt Augustin, and University Hospital of Cologne, Cologne, Germany; ⁸Prof Hess Children's Hospital and Pediatric Intensive Care Medicine, Bremen, Germany; ⁹German Rheumatism Research Centre Berlin, and

This article has been accepted for publication in The Journal of Rheumatology following full peer review. This version has not gone through proper copyediting, proofreading and typesetting, and therefore will not be identical to the final published version. Reprints and permissions are not available for this version. Please cite this article as doi 10.3899/jrheum.180795. This accepted article is protected by copyright. All rights reserved.

Charité University Medicine, Department of Rheumatology and Clinical Immunology, Berlin, Germany; ¹⁰Hospital for Special Surgery, Division of Pediatric Rheumatology, New York, New York; ¹¹Connecticut Children's Medical Center, Pediatric Rheumatology, Hartford, Connecticut; ¹²Tulsa Bone & Joint Associates, Tulsa, Oklahoma; ¹³National Referral Centre of Auto-Inflammatory Diseases, CEREMAIA, CHU de Bicere, Department of Pediatric Rheumatology, APHP, University of Paris Sud, Le Kremlin Bicêtre, France; ¹⁴University Hospital of Ioannina, Unit of Paediatric Rheumatology, Paediatric Clinic, Ioannina, Greece; ¹⁵Children's Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Pediatric Rheumatology Unit, Sao Paulo, Brazil; ¹⁶Genentech, South San Francisco, California; ¹⁷University of Cincinnati, Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Department of Pediatrics, PRCSG Coordinating Center, Cincinnati, Ohio

*Contributed equally to the study

¶Affiliation at the time the study was conducted

Running head: Neutropenia in tocilizumab-treated children

Funding: The study was sponsored by F. Hoffmann La Roche Ltd. Support for third-party writing assistance was provided by Sara Duggan, PhD, of ApotheCom and was funded by F. Hoffmann La Roche Ltd.

Corresponding author:

Fabrizio De Benedetti, MD, PhD
IRCCS Ospedale Pediatrico Bambino Gesù
Piazza S. Onofrio 4
00165 Rome, Italy
Tel. 39 06 68594393
Fax. 39 06 68594394
E-mail: fabrizio.debenedetti@opbg.net

Word count: 3625 <<maximum, 3500>>

Tables/figures: 2/3 <<maximum, 6>>

References: 42 <<maximum, 50>>

ABSTRACT: <<231/maximum 250 words>>

Objective. To determine whether neutropenia is associated with increased risk for infection in patients with systemic juvenile idiopathic arthritis (sJIA) and polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with tocilizumab (TCZ).

Methods. Data up to week 104 from 2 phase 3 trials of intravenous TCZ in sJIA (n = 112; ClinicalTrials.gov, NCT00642460) and pcJIA (n = 188; ClinicalTrials.gov, NCT00988221) were pooled. Worst Common Toxicity Criteria grade and lowest observed absolute neutrophil count (ANC) were identified for each patient. Associations between patient characteristics and lowest observed ANC were tested using univariate regression analysis. Infection and serious infection rates (per 100 patient-years [PY]) in periods associated with grades 1/2 and 3/4 neutrophil counts were compared with rates associated with normal neutrophil counts.

Results. ANCs decreased to grade ≥ 3 in 25.0% and 5.9% of sJIA and pcJIA patients, respectively, and decreases were transient. Young age ($p = 0.047$) and methotrexate use ($p = 0.012$) were positively associated with neutropenia in patients with sJIA but not in patients with pcJIA. The rate of serious infections in patients with sJIA (10.9/100 PY; 95% CI, 6.8-16.5) tended to be higher than in patients with pcJIA (5.2/100 PY; 95% CI, 3-8.5). No increase in rates of serious or nonserious infections was observed during periods of neutropenia in either trial.

Conclusion. Patients with JIA treated with TCZ experienced transient neutropenia that was not associated with an increased number of infections.

Key Indexing Terms: BIOLOGICAL THERAPY, INFECTION, JUVENILE IDIOPATHIC ARTHRITIS, NEUTROPHILS

Interleukin-6 (IL-6) is a cytokine implicated in many aspects of inflammation^{1, 2}, making it an attractive target for treating a variety of chronic inflammatory diseases. Clinical trials have demonstrated the efficacy and safety of the anti–interleukin-6 receptor-alpha antibody tocilizumab (TCZ) in treating rheumatoid arthritis (RA)³⁻⁸, giant cell arteritis⁹, systemic juvenile idiopathic arthritis (sJIA), and polyarticular-course juvenile idiopathic arthritis (pcJIA)^{10, 11}.

Neutropenia was reported in all clinical trials performed with TCZ. In RA trials, 4.8% of patients reported common toxicity criteria (CTC)¹² grade 3 (absolute neutrophil count [ANC] $0.5 < 1 \times 10^9/L$) neutropenia, and 0.7% reported grade 4 (ANC $< 0.5 \times 10^9/L$) neutropenia¹³. Grade 3 or grade 4 neutropenia was also observed in phase 3 clinical trials in children with sJIA and with pcJIA; frequencies were 25.0% and 5.9 % of patients, respectively, during 2 years of treatment with TCZ^{14, 15}. In RA patients, neutropenia associated with TCZ administration was usually transient (90% of patients with grade 3 or 4 neutropenia experienced it on only a single visit, 2 consecutive visits, or nonconsecutive visits) and did not lead to treatment discontinuation¹⁶. However, the potential relationship between decreased neutrophil count and increased risk for infection remains a cause of concern, particularly in children treated with TCZ.

Treatment with sarilumab, another anti–IL-6R monoclonal antibody, leads to similar effects on neutrophils¹⁷. The mechanism leading to reduced neutrophil counts during IL-6R blockade remains unknown. Although IL-6 has been shown to have a role in the stimulation of hematopoietic progenitor stem cells¹⁸, a direct role on neutropoiesis has not been clearly demonstrated. IL-6 knockout (KO) mice do not show neutropenia; however, crossing the severely neutropenic granulocyte–colony-stimulating factor (G-CSF) receptor KO mice with IL-6 KO mice led to further decrease in neutrophil counts, suggesting that IL-6 might play a role in this extreme situation¹⁹.

Some studies have suggested several potential mechanisms, including increased neutrophil apoptosis and reduced neutrophil survival, increased margination and/or migration/trafficking of neutrophils in peripheral tissue, and decreases in other proinflammatory cytokines, including those that have an effect on neutropoiesis²⁰⁻²².

We performed a secondary analysis of the data from the 2 pivotal phase 3 clinical trials of TCZ in patients with sJIA¹⁰ and pcJIA¹¹ to investigate variables possibly associated with reduced neutrophil counts and to evaluate their relationship to the development of serious and nonserious infections.

METHODS

Patients and study designs. TENDER (ClinicalTrials.gov, NCT00642460) was a 5-year, phase 3 study that assessed the efficacy and safety of intravenous TCZ in 112 patients with sJIA aged 2 to 17 years as defined by criteria of the International League of Associations for Rheumatology (ILAR)²³ that was active and was of ≥ 6 months' duration. Weight-adjusted TCZ doses were administered: patients were randomly assigned to receive TCZ (12 mg/kg for body weight < 30 kg or 8 mg/kg for body weight ≥ 30 kg) or placebo every 2 weeks. Patients who had baseline white blood cell counts $< 5.0 \times 10^9/L$ and neutrophil counts $< 2.5 \times 10^9/L$ were excluded from enrolling. Additional details are included in the Appendix and have been published¹⁰.

CHERISH (ClinicalTrials.gov, NCT00988221) was a 2-year, 3-part, randomized, double-blind, placebo-controlled withdrawal study of the efficacy and safety of TCZ in 188 patients aged 2 to 17 years with rheumatoid factor (RF)-positive or RF-negative pcJIA or extended oligoarticular juvenile idiopathic arthritis (JIA) with polyarticular course for ≥ 6 months before study entry according to ILAR criteria²³. Part 1 was a 16-week, active-treatment period during which patients who weighed ≥ 30 kg received TCZ 8 mg/kg and patients who weighed < 30 kg were randomly assigned 1:1 to

receive TCZ 8 mg/kg or 10 mg/kg every 4 weeks for 4 doses. Patients who achieved at least a JIA ACR30 response at week 16 could enter part 2 (24-week, double-blind, placebo-controlled withdrawal period) and were randomly assigned to receive placebo or to continue TCZ at the same dose received in part 1. Part 3 was an additional 64-week, open-label TCZ extension period. Patients with baseline white blood cell counts $<5.0 \times 10^9/L$ and those with neutrophil counts $<2.5 \times 10^9/L$ were excluded. Additional details of the CHERISH trial are published¹¹. Data up to week 104 from patients with sJIA in the TENDER trial and patients with pcJIA in the CHERISH trial were pooled for the current analysis.

Both studies were conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local requirements, and both were approved by the institutions' Research Ethics Boards (the approval number for the principal trial site 165340 for CHERISH was 73/2009 and the approval number for TENDER was 220 VA/cm). Parents or guardians provided written informed consent and patients provided written informed assent.

Study assessments. Blood cell counts were monitored at each study visit in both studies. According to the study protocols, TCZ administration was delayed if patients had neutrophil counts lower than $1 \times 10^9/L$. Infection adverse events (AEs) were identified and reported as per the Medical Dictionary for Regulatory Activities (MedDRA) system organ class code of Infections and Infestations. TCZ serum concentrations were measured using an enzyme-linked immunosorbent assay by (Endo Drug Development, Dublin, Ireland)²⁴.

Statistical analysis. Analysis included the all-exposure safety population (all patients who received ≥ 1 dose of TCZ and who underwent ≥ 1 safety assessment after TCZ administration). Placebo treatment periods for patients who received placebo in part 1 of TENDER and part 2 of CHERISH, respectively, were excluded from the analysis unless stated otherwise. Worst CTC neutropenia grade and lowest neutrophil counts ($10^9/L$) were graded for each patient using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0¹². The grading system

classifies severity of neutropenia as follows: grade 0, normal; grade 1, $<$ lower limit of normal (LLN) to $1.5 \times 10^9/L$; grade 2, <1.5 to $1.0 \times 10^9/L$; grade 3, <1.0 to $0.5 \times 10^9/L$; and grade 4, $<0.5 \times 10^9/L$. The LLN used in the definition of grade 1 low neutrophil count was age and sex specific for this pediatric population.

Associations between patient characteristics at baseline, concomitant treatments, and patients' TCZ exposure estimated by the average C_{trough} at the time of the lowest observed neutrophil counts were determined using univariate linear regression analysis. Variables that might have affected neutrophil counts were preselected for inclusion in the regression analysis. All variables analyzed were included in the results. Rates of infection and serious infection (Appendix) associated with neutropenia episodes were compared with corresponding rates associated with periods of normal neutrophil counts.

RESULTS

Baseline demographics and disease characteristics. Baseline demographics and disease characteristics of all patients are shown in Table 1. At baseline, oral glucocorticoids were used by 91% (102/112) of patients with sJIA at a mean (SD) dose of 0.3 (0.18) mg/kg/day; 69% (77/112) of these patients received methotrexate (MTX) (mean [SD] dose, 13.7 [8.4] mg/m²/week). Among the patients with pcJIA, 46% (86/188) were treated with glucocorticoids at baseline (mean [SD] dose, 0.13 [0.05] mg/kg/day); 79% (148/188) received MTX (mean [SD] dose, 13.0 [5.8] mg/m²/week). Differences in demographics and characteristics between the groups (body weight ≥ 30 kg vs body weight <30 kg), including age, weight, and disease duration, were as expected according to the body weight–based dosing regimens.

Neutrophil count during treatment with tocilizumab. At baseline, the median (interquartile range [IQR]) ANC among patients with sJIA was $8.13 (6.52\text{--}12.89) \times 10^9/L$. Approximately 50% of

patients had ANC's exceeding their age-specific upper limit of normal range, and no patients had ANC's below normal at baseline. Median ANC decreased from $8.13 \times 10^9/L$ at baseline to $3.93 \times 10^9/L$ within 2 weeks of the initiation of TCZ treatment, then stabilized and remained within the normal range up to week 104 in the group of patients with sJIA (Figure 1A). Notably, 44.6% (n = 50) of patients with sJIA had normal ANC's or grade 1 neutropenia throughout the study. Grade 2 neutropenia occurred in 34 patients (30.4%), grade 3 in 26 patients (23.2%), and grade 4 in 2 patients (1.8%) (Table 2). A numerically higher proportion of patients weighing <30 kg (36% [21/58]) than patients weighing ≥ 30 kg (13.0% [7/54]) had CTC grade 3/4 neutropenia. In total, it occurred in 28 patients (2 had grade 4); in 14 of those patients, it occurred only once during the trial. One patient experienced 3 episodes of grade 3/4 neutropenia that lasted up to 14 days each. Grade 3 neutropenia occurred only once during an episode of macrophage activation syndrome (MAS); the other 4 episodes of potential or definite MAS observed in TENDER did not occur with low ANC's.

In patients with pcJIA, the median (IQR) baseline ANC was 4.8 (3.6-6.0) $\times 10^9/L$ for all patients. Approximately 7% of these patients had ANC's exceeding the upper limit of normal, and no patients had neutrophil counts below normal at baseline. The median ANC decreased after TCZ initiation and stabilized after week 16; similar patterns were observed in patients with pcJIA who received placebo in part 2 of the study (Figure 1B). Overall, 70.7% (n = 133) of patients had normal or only minimally decreased ANC (grade 1) throughout the study; CTC grade 2 or 3 neutropenia was reported in 44 (23.4%) or 11 (5.9%) patients, respectively. None of the patients with pcJIA experienced grade 4 neutropenia (Table 2). A greater proportion of patients with pcJIA weighing <30 kg and receiving TCZ 10 mg/kg (10.1% [7/69]) experienced episodes of grade 3 neutrophil counts than patients weighing ≥ 30 kg and receiving TCZ 8 mg/kg (3.4% [4/119]).

Among these 11 patients with CTC grade 3 neutropenia, 8 experienced neutropenia only once, 2

experienced nonconsecutive episodes of neutropenia, and 1 experienced grade 3 neutropenia at 3 consecutive time points over a duration of 60 days.

Factors associated with the development of neutropenia during tocilizumab treatment. Univariate linear regression analysis was used to explore the association between baseline age, glucocorticoid and MTX use and dose, and TCZ C_{trough} at the time of the lowest ANC (Figures 2A and 2B).

In patients with sJIA, though neither glucocorticoid use (yes vs no; absolute or weight-adjusted dose; regression coefficient [95% CI] = 0.35 [−0.39, 1.10]; $p = 0.348$ or 0.27 [−0.81, 1.35]; $p = 0.616$) nor TCZ C_{trough} (regression coefficient [95% CI] = −0.35 [−1.11, 0.42]; $p = 0.367$) was associated with the lowest ANC, younger age showed a weak, though significant, positive association (regression coefficient [95% CI] = 0.47 [0.01, 0.93]; $p = 0.047$). Additionally, background MTX use was significantly associated with the lowest ANC (regression coefficient [95% CI] = −0.58 [−1.02, −0.13]; $p = 0.012$), and there was a trend toward association with the MTX dose ($\text{mg}/\text{m}^2/\text{week}$) and the minimum ANC (regression coefficient [95% CI] = −0.22 [−0.45, 0.00]; $p = 0.051$) (Figure 2A). None of these associations found in patients with sJIA were observed in patients with pcJIA (Figure 2B). Neutropenia was not associated with exposure to TCZ as measured by TCZ trough levels (regression coefficient [95% CI] = −0.04 [−0.14, 0.06]; $p = 0.417$) (Figure 2B).

Infections and serious infections during treatment with tocilizumab. Among patients with sJIA, 13 infection AEs (243.7/100 PY) were reported for 29.7% of patients during placebo exposure compared with 46 infection AEs (267.6/100 PY) reported for 45.3% of patients during TCZ exposure. By week 104, 102 of 112 (91.1%) patients reported a total of 570 infection AEs (282.1/100 PY). Overall, the most frequently reported infections were nasopharyngitis and upper respiratory tract infections. In patients with sJIA treated with TCZ, 22 serious infection AEs developed in 20 patients (17.9%), corresponding to a rate of 10.9/100 PY. There were 4 events each (2.0/100 PY) of gastroenteritis and varicella, 3 events (1.5/100 PY) of pneumonia, and 2 events

(1.0/100 PY) of herpes zoster. All cases of varicella or herpes zoster were treated with acyclovir, and all resolved without sequelae. All other serious infections were single events and also resolved without sequelae.

Among patients with pcJIA, 465 infection AEs (151.4/100 PY) were reported for 134 of 188 patients (71.3%) by week 104. The most frequently reported infections were nasopharyngitis (27.4/100 PY), upper respiratory tract infection (15.3/100 PY), and pharyngitis (11.7/100 PY).

Overall, 16 serious infections were reported in 14 patients with pcJIA (7.4%), corresponding to a rate of 5.2/100 PY during TCZ treatment. There were 4 events (1.3/100 PY) of pneumonia and 2 events each (0.7/100 PY) of bronchitis, cellulitis, and varicella. One case of varicella was untreated and 1 was treated with acyclovir; both resolved without sequelae. All other serious infections were single events and also resolved during the study period.

Relationship between infection and neutropenia. Among patients with sJIA, the rate of infection AEs was comparable between periods of normal (276.5/100 PY), grade 1/2 (226.7/100 PY), and grade 3/4 neutropenia (292.5/100 PY) (Figure 3A). Infections occurring around periods of grade 1/2 neutropenia included nasopharyngitis (15 events), upper respiratory tract infection (9 events), pharyngitis (4 events), and impetigo and urinary tract infection (3 events each). The remaining reported infections were also single events. Infections occurring around periods of grade 3/4 neutropenia included upper respiratory tract infection (5 events), nasopharyngitis (3 events), gastroenteritis and conjunctivitis (2 events each), and pneumonia, rhinitis, viral infection, and subcutaneous abscess (1 event each). No serious infections were reported around episodes of grade 3 or 4 neutropenia, but 2 serious infections were reported with grade 1/2 neutropenia (8.7/100 PY), which is similar to the rate of infection AEs (11.5/100 PY) observed during periods of normal neutrophil counts (Figure 3B).

Among patients with pcJIA, rates of infection AEs during periods of normal, grade 1/2, and grade 3/4 neutropenia were 147.8/100 PY, 176.6/100 PY, and 340/100 PY, respectively, with largely

overlapping confidence intervals (Figure 3C). Infections occurring around periods of grade 1/2 neutropenia included nasopharyngitis (6 events), upper respiratory tract infection (6 events), pharyngitis (4 events), respiratory tract infection (3 events), and gastroenteritis, influenza, pediculosis, localized infection, and rhinitis (2 events each). All other infections were single events. Infections with grade 3/4 neutropenia included upper respiratory tract infection and influenza (2 events each) and mumps, tracheitis, and nasopharyngitis (1 event each). No serious infections were reported around episodes of neutropenia of any grade. All 16 serious infections occurred during periods of normal neutrophil counts and ≥ 30 days from neutrophil counts below the lower limit of normal (Figure 3D).

DISCUSSION

Neutropenia was reported in the 2 pivotal trials of TCZ in patients with JIA, with grade ≥ 3 events occurring in 19 of 112 patients with sJIA (17%) after 52 weeks¹⁰ and in 7 of 188 patients with pcJIA (3.7%) after 40 weeks¹¹. This secondary analysis included data for up to 2 years of TCZ treatment in each trial, identified potential risk factors for the development of neutropenia, and investigated whether there was a temporal association between neutropenia and the occurrence of infections. In this analysis, grade ≥ 3 neutropenia was observed in 25.0% of the patients with sJIA and in 5.9% of the patients with pcJIA. Risk factors for neutropenia included young age and MTX use in patients with sJIA but not in patients with pcJIA. Rates of infection (serious or nonserious) were similar during times of normal or near-normal ANC (grade 1 and grade 2 neutropenia) and periods of more pronounced reduction of neutrophil counts (grade 3 or 4 neutropenia) in patients with sJIA and in those with pcJIA. Grade ≥ 3 neutropenia has been reported in clinical trials of TCZ in patients with RA. In a recent long-term pooled analysis of the pivotal phase 3 and 4 clinical trials of TCZ in RA (16,204.8 PY of TCZ exposure), grade 3 neutropenia occurred in 5.4% of patients and grade 4 neutropenia occurred in <1% of patients¹⁸. In a pooled analysis of neutropenia in

patients with pcJIA (5.9%) reported here is comparable to that reported in patients with RA. As might be expected, neutropenia was more common among RA patients who received TCZ 8 mg/kg than those who received TCZ 4 mg/kg per month^{4, 6}. Together with the data from patients with sJIA reported here, this suggests that higher TCZ exposure is associated with more frequent neutropenia^{4, 6}. However, we did not observe a direct relationship between TCZ mean serum concentrations and ANC in patients with sJIA or in those with pcJIA. This suggests that other factors may also contribute to the development of decreases in neutrophil count. Although this study lacked the power for more informative multivariate analysis, it is worth noting that, based on univariate analysis, MTX background therapy was a risk factor for neutropenia in patients with sJIA. However, it was not a risk factor in patients with pcJIA and has not been reported as a risk factor in patients with RA treated with TCZ³. Moreover, in a meta-analysis of Japanese patients with RA treated with TCZ monotherapy, the incidence of grade 3 neutropenia (6%)²⁵ was not different from that reported in global trials in which TCZ was used in combination with MTX¹⁶. It is possible that other disease-related factors are involved in the development of neutropenia or that the effect of MTX on neutrophil counts is evident only with higher doses of TCZ, such as those administered to patients with sJIA. Given the limited, if any, efficacy of MTX in sJIA²⁶, holding TCZ is recommended in patients with neutrophil counts $<1.0 \times 10^9/L$, and withdrawing MTX or dose reduction might be considered.

It is well known that the use of glucocorticoids is associated with neutrophilia because glucocorticoids inhibit neutrophil apoptosis in humans²⁷. The current analysis showed that glucocorticoid use (yes or no) and weight-adjusted glucocorticoid dose were not significantly associated with lowest neutrophil count. This finding suggests that glucocorticoid treatment does not mask neutropenia in patients treated with TCZ. It should be noted that a potential limitation in the current study is the reduction in glucocorticoid dose over the course of the study as patients' disease improved.

In both sJIA and pcJIA, children in the lower weight category had a higher frequency of grade 3 neutropenia; analysis of the relationship between lowest neutrophil count and several variables showed a significant association only for age and only in patients with sJIA. It is well known that the prevalence of neutropenia is higher in younger subjects. In a US-based epidemiological study, neutropenia was observed in 3.7% of children aged 3 to 5 years but in only 1.5% of adolescents aged 15 to 17 years and in 0.72% of adults²⁸.

Our data support the finding that the rate of serious infections in children with sJIA treated with TCZ (10.9/100 PY; 95% CI, 6.8-16.5) tends to be higher than in children with pcJIA treated with TCZ (5.2/100 PY; 95% CI, 3-8.5) and still higher than reported in adult patients with RA treated with TCZ with or without MTX (4.4/100 PY; 95% CI, 4.1-4.8)¹⁶. This result is consistent with observations of other treatments previously reported. For example, in patients with sJIA treated with anakinra, the rate of infections was approximately 6/100 PY in a multicenter retrospective case series of 46 patients²⁹ and 26/100 PY in a randomized, double-blind, placebo-controlled study in 22 patients³⁰. Similarly, in a large US report on infections in patients with JIA, Beukelman et al³¹ showed a risk for infections requiring hospital admission in anakinra users (primarily patients with sJIA) at a rate of 8.4/100 PY. In agreement with these findings, preliminary results from the Pharmachild Registry showed that the risk for infection was significantly increased in patients with sJIA (approximately 2-fold higher) than in patients with other JIA subtypes³². Indeed, the rate of serious infection reported in trials of patients with pcJIA treated with tumor necrosis factor inhibitors ranges from 2/100 PY to 4/100 PY^{33, 34}. These numbers are consistent with a recent large study in patients with JIA observed for approximately 13,000 PY that showed an overall rate of 2.8/100 PY for bacterial infections that necessitated hospital admission, which was 2-fold higher than in the control population (patients with attention-deficit hyperactivity disorder) and 3.5-fold higher in patients who received tumor necrosis factor inhibitors with or without MTX³⁵.

Accepted Article
Altogether, the data reported here support the idea that susceptibility to infections is a feature of JIA and the conclusion that inflammation/autoimmunity predisposes children to infections; this predisposition may be amplified by individual treatments. Furthermore, glucocorticoids, particularly at high doses, are known to increase the risk for infections in adults with RA³⁶⁻³⁹ and in children with JIA^{32, 35}. Patients with sJIA are more commonly treated with higher doses of glucocorticoids than patients with pcJIA; this was also true for the populations analyzed in this study.

In the sJIA and the pcJIA trials, we found a numerically higher rate of infections around grade 3 or 4 neutropenia than around normal or grade 1 or 2 neutropenia; however, serious infections were not more commonly reported during periods of grade 3 and 4 neutropenia than around normal or grade 1 and 2 neutropenia. It is worth noting that we evaluated the occurrence of infections during grade ≥ 3 neutropenia over a duration of 5.5 years in patients with sJIA and 2.1 years in patients with pcJIA. In a recent observational study in patients with severe congenital neutropenia, the rate of serious infection was 232/100 PY before the administration of G-CSF and 38/100 PY after diagnosis and the administration of G-CSF⁴⁰.

A number of hypotheses may be consistent with the lack of an association between decreased ANC's during TCZ treatment and the occurrence of infections. It is possible that blockade of IL-6 may modulate the circulating pool of neutrophils by shifting them from the circulating to the marginated pools^{21, 41}, or increasing their transit time through the bone marrow, or both^{21, 42}. Moreover, after TCZ administration, neutrophils are fully functional and show no impairment in their antibacterial functions⁴⁰.

In conclusion, our findings indicate that neutropenia in patients with sJIA and patients with pcJIA who were treated with TCZ was transient and was not associated with the development of infections and serious infections.

ACKNOWLEDGMENTS

The authors thank the patients who were enrolled in this study and their families. They extend special thanks to all the trial investigators for their energy and commitment.

CONFLICTS OF INTEREST

Manuela Pardeo: Nothing to disclose

Jianmei Wang: Employee of Roche (>\$10,000)

Nicolino Ruperto: Consultant/speaker: AbbVie, Amgen, Biogenidec, Alter, AstraZeneca, Baxalta

Biosimilars, Biogenidec, Boehringer, BMS, Celgene, CrescendoBio, EMD Serono, Hoffmann-La

Roche, Italfarmaco, Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis,

Servier, Takeda, UCB Biosciences GmbH (<\$10,000 each)

Ekaterina Alexeeva: Consultant/speaker: F. Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb,

Centocor, Novartis (<\$10,000)

Vyacheslav Chasnyk: Nothing to disclose

Rayfel Schneider: Nothing to disclose

Gerd Horneff: Speaker: Chugai, Assure, Pfizer, Novartis, Merck Sharp & Dohme (<\$10,000 each)

Hans-Iko Huppertz: Nothing to disclose

Kirsten Minden: Consultant/speaker/honoraria: AbbVie, Pfizer, Roche, Chugai, Allergan, Medac

(<\$10,000 each)

Karen Onel: Nothing to disclose

Lawrence Zemel: Nothing to disclose

Alan L Martin: Nothing to disclose

Isabelle Koné-Paut: Consultant to Roche (<\$10,000)

Antigoni Siamopoulou: Nothing to disclose

Clovis A. Silva: Nothing to disclose

Benjamin Porter-Brown: Employee of and stock ownership in Roche (>\$10,000)

Kamal Bharucha: Employee of Genentech and stock ownership in Roche (>\$10,000)

Hermine I Brunner: Consultant/speaker/honoraria: AbbVie, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Janssen, Takeda, UCB; Roche/Genentech, Novartis, Pfizer, Bristol-Myers Squibb (<\$10,000 each)

Fabrizio De Benedetti: Consultant/speaker/honoraria: Roche, Novartis, Novimmune, SOBI, Sanofi (<\$10,000 each)

AUTHOR CONTRIBUTIONS

The first draft of the manuscript was written by Drs Pardeo, Wang, and De Benedetti and was revised critically by Drs Ruperto and Brunner. All authors were involved in revising subsequent drafts of the manuscript critically for important intellectual content, and all approved the final draft for submission.

Study conception and design: Wang, Ruperto, Porter-Brown, Bharucha, Brunner, De Benedetti

Acquisition of data: Pardeo, Wang, Ruperto, Alekseeva, Chasnyk, Schneider, Horneff, Huppertz, Minden, Onel, Zemel, Martin, Koné-Paut, Siamopoulou-Mavridou, Silva, Brunner, De Benedetti

Analysis and interpretation of data: Pardeo, Wang, Ruperto, Horneff, Onel, Zemel, Martin, Porter-Brown, Bharucha, Brunner, De Benedetti

REFERENCES

1. Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. *Arthritis Res Ther* 2006;8:S5.
2. Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. *Rheumatology* 2014;53:1321-31.
3. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis Rheum* 2006;54:2817-29.
4. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* 2008;371:987-97.
5. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum* 2008;58:2968-80.
6. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis* 2008;67:1516-23.
7. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis* 2010;69:88-96.

8. Kremer JM, Blanco R, Brzosko S, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. *Arthritis Rheum* 2011;63:609-21.
9. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med* 2017;377:317-28.
10. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Inmaculada C, Cuttica R, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. *N Engl J Med* 2012;367:2385-95.
11. Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. *Ann Rheum Dis* 2014;74:1110-7.
12. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE).
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae3.pdf.
Accessed July 2, 2018.
13. Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gomez-Reino J, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. *J Rheumatol* 2013;40:768-80.
14. De Benedetti F, Rubio-Perez N, Goodman S, Job-Delandre C, Joos R, Kone-Paut I, et al. Neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis. *Arthritis Rheumatol* 2014;66:S67-8.

15. De Benedetti F, Ruperto N, Baildam E, Burgos-Vargas R, Horneff G, Iko Huppertz H, et al. Neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with systemic juvenile idiopathic arthritis. *Arthritis Rheumatol* 2014;66:S23-4. A14.
16. Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F, et al. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. *Rheumatology* 2017;56:541-9.
17. Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. *Ann Rheum Dis* 2014;73:1626-34.
18. Rennick D, Jackson J, Yang G, Wideman J, Lee F, Hudak S. Interleukin-6 interacts with interleukin-4 and other hematopoietic growth factors to selectively enhance the growth of megakaryocytic, erythroid, myeloid, and multipotential progenitor cells. *Blood* 1989;73:1828-35.
19. Liu F, Poursine-Laurent J, Wu HY, Link DC. Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. *Blood* 1997;90:2583-90.
20. Gibiansky L, Frey N. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. *J Pharmacokinet Pharmacodyn* 2012;39:5-16.
21. Suwa T, Hogg JC, English D, van Eeden SF. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. *Am J Physiol Heart Circ Physiol* 2000;279:H2954-60.
22. Lok LSC, Farahi N, Juss JK, Loutsious C, Solanki CK, Peters AM, et al. Effects of tocilizumab on neutrophil function and kinetics. *J Clin Invest* 2017;47:736-45.

23. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J Rheumatol* 2004;31:390-2.
24. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleyen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. *Clin Ther* 2010;32:1597-609.
25. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. *Mod Rheumatol* 2010;20:222-32.
26. Woo P, Southwood TR, Prieur A-M, Doré CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. *Arthritis Rheum* 2000;43:1849-57.
27. Saffar AS, Ashdown H, Gounni AS. The molecular mechanisms of glucocorticoids-mediated neutrophil survival. *Curr Drug Targets* 2011;12:556-62.
28. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. *Ann Intern Med* 2007;146:486-92.
29. Nigrovic PA, Mannion M, Prince FH, Zeff A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. *Arthritis Rheum* 2011;63:545-55.
30. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist

anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). *Ann Rheum Dis* 2011;70:747-54.

31. Beukelman T, Xie F, Baddley JW, Chen L, Mannion ML, Saag KG, et al. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. *Arthritis Res Ther* 2016;18:210.
32. Giancane G, Swart J, Bovis F, Castagnola E, Groll A, Horneff G, et al. Risk of infections in juvenile idiopathic arthritis patients treated with biologic agents and/or methotrexate: results from Pharmachild Registry. *Arthritis Rheumatol* 2017;68(suppl 10).
33. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. *N Engl J Med* 2008;359:810-20.
34. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum* 2006;54:1987-94.
35. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. *Arthritis Rheum* 2012;64:2773-80.
36. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum* 2002;46:2287-93.
37. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. *Arthritis Rheum* 2002;46:2294-300.
38. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. *J Rheumatol* 2008;35:387-93.
39. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. *Rheumatology* 2007;46:1157-60.

40. Fioredda F, Calvillo M, Burlando O, Riccardi F, Caviglia I, Tucci F, et al. Infectious complications in children with severe congenital, autoimmune or idiopathic neutropenia: a retrospective study from the Italian Neutropenia Registry. *Pediatr Infect Dis J* 2013;32:410-2.
41. Hashizume M, Higuchi Y, Uchiyama Y, Mihara M. IL-6 plays an essential role in neutrophilia under inflammation. *Cytokine* 2011;54:92-9.
42. Suwa T, Hogg JC, Klut ME, Hards J, van Eeden SF. Interleukin-6 changes deformability of neutrophils and induces their sequestration in the lung. *Am J Respir Crit Care Med* 2001;163:970-6.

FIGURE LEGENDS

Figure 1. (A) Median (IQR) neutrophil count in sJIA patients treated with TCZ for up to 2 years. (B) Median (IQR) neutrophil count in pcJIA patients stratified by part 2 randomized treatment. IQR: interquartile range; pcJIA: polyarticular-course juvenile idiopathic arthritis; sJIA: systemic juvenile idiopathic arthritis; TCZ: tocilizumab.

Figure 2. Association between baseline and pharmacokinetic variables with neutrophil counts based on univariate regression analysis in (A) patients with sJIA and (B) patients with pcJIA. Differences are regression coefficients against each variable. For example, 0.47 for age (A) means that older age (per 10 years) corresponds to an increase in the lowest neutrophil count by $0.47 \times 10^9/L$. CI: confidence interval; C_{trough} : within-subject average trough TCZ concentration; MTX: methotrexate; pcJIA: polyarticular-course juvenile idiopathic arthritis; sJIA: systemic juvenile idiopathic arthritis; TCZ: tocilizumab.

Figure 3. Rates of (A) infection and (B) serious infection during ± 15 days of normal neutrophil count, grade 1 or 2 neutrophil count, and grade 3 or 4 neutrophil count in patients with sJIA treated with tocilizumab. Rates of (C) infection and (D) serious infection during ± 30 days of normal neutrophil count, grade 1 or 2 neutrophil count, and grade 3 or 4 neutrophil count in patients with pcJIA treated with tocilizumab. AE: adverse event; CTC: Common Toxicity Criteria; pcJIA: polyarticular-course juvenile idiopathic arthritis; PY: patient-years; sJIA: systemic juvenile idiopathic arthritis.

Table 1. Baseline demographics and disease characteristics of all patients

Characteristic	sJIA			pcJIA		
	All	BW <30 kg	BW ≥30 kg	All	BW <30 kg	BW ≥30 kg
	N = 112	n = 58	n = 54	N = 188	n = 69	n = 119
Mean age, years (SD)	9.7 (4.6)	6.4 (3.2)	13.2 (2.9)	11.0 (4.0)	7.2 (2.9)	13.1 (2.8)
Female, n (%)	56 (50)	27 (47)	29 (54)	144 (77)	54 (78)	90 (76)
Mean body weight, kg (SD)	33.8 (19.6)	20.1 (5.9)	48.5 (18.5)	39.6 (17.3)	21.5 (5.5)	50.0 (12.6)
Mean disease duration, years (SD)	5.2 (4.1)	3.7 (3.1)	6.7 (4.5)	4.2 (3.7)	3.5 (2.46)	4.7 (4.2)
Mean baseline neutrophil count, 10 ⁹ /L (SD)	10.7 (6.9)	11.4 (7.4)	9.9 (6.3)	5.4 (3.2)	5.6 (2.0)	5.2 (3.7)
Baseline GC use, n (%)	102 (91)	56 (97)	46 (85)	86 (46)	33 (48)	53 (45)
Mean baseline GC dose, ^a	0.33 (0.18)	0.39 (0.18)	0.26 (0.16)	0.13 (0.05)	0.15 (0.04)	0.12 (0.05)

mg/kg/day
(SD)

Baseline MTX use, n (%)	77 (69)	46 (79)	31 (57)	148 (79)	59 (86)	89 (75)
Mean baseline MTX dose, ^a mg/week (SD)	13.7 (8.4)	13.1 (10.1)	14.6 (4.8)	13.0 (5.8)	15.1 (8.1)	11.6 (2.7)

Patients with sJIA weighing <30 kg received TCZ 12 mg/kg every 2 weeks, and those weighing ≥30 kg received TCZ 8 mg/kg every 2 weeks. Patients with pcJIA weighing <30 kg received TCZ 8 mg/kg or TCZ 10 mg/kg every 4 weeks, and those weighing ≥30 kg received TCZ 8 mg/kg every 4 weeks.

^aMean dose based on patients who were taking GC or MTX only.

BW: body weight; GC: glucocorticoids; MTX: methotrexate; pcJIA: polyarticular-course juvenile idiopathic arthritis; SD: standard deviation; sJIA: systemic juvenile idiopathic arthritis.

Table 2. Worst CTC grade of neutropenia during the first 2 years of TCZ treatment in sJIA and pcJIA patients by BW group

CTC Grade	sJIA			pcJIA		
	All	BW <30 kg	BW ≥30 kg	All	BW <30 kg	BW ≥30 kg
	N = 112	n = 58	n = 54	N = 188	n = 69	n = 119
Grade 0-1, n (%)	50 (44.6)	21 (36.2)	29 (53.7)	133 (70.7)	49 (71.0)	84 (70.6)
1.5 × 10 ⁹ /L to normal						
Grade 2, n (%)	34 (30.4)	16 (27.6)	18 (33.3)	44 (23.4)	13 (18.8)	31 (26.1)
1.0 to <1.5 × 10 ⁹ /L						
Grade 3, n (%)	26 (23.2)	19 (32.8)	7 (13.0)	11 (5.9)	7 (10.1)	4 (3.4)
0.5 to <1.0 × 10 ⁹ /L						
Grade 4, n (%)	2 (1.8)	2 (3.4)	0	0	0	0
<0.5 × 10 ⁹ /L						

Patients with sJIA weighing <30 kg received TCZ 12 mg/kg every 2 weeks, and those weighing ≥30 kg received TCZ 8 mg/kg every 2 weeks. Patients with pcJIA weighing <30 kg received TCZ 8 mg/kg or TCZ 10 mg/kg every 4 weeks, and those weighing ≥30 kg received TCZ 8 mg/kg every 4 weeks.

BW: body weight; CTC: Common Toxicity Criteria; pcJIA: polyarticular-course juvenile idiopathic arthritis; sJIA: systemic juvenile idiopathic arthritis; TCZ: tocilizumab.